09/830744

L Number	Hits	Search Text	DB	Time stamp
1	54180	polysaccharide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:45
2	8944	polysaccharide and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:46
3	1052	(polysaccharide and cross-link$) and polyamine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
4	328	((polysaccharide and cross-link$) and polyamine) and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
5	94	(((polysaccharide and cross-link$) and polyamine) and carboxy) and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
6	6568	polysaccharide and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
7	2134	(polysaccharide and carboxy) and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
8	476	((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
9	0	(((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and hyaluronicl4 and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
10	80	(((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
11	67	(((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and chitin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
12	535	536/21	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
13	94	536/21 and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
14	27	(536/21 and cross-link$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18

15	6	((536/21 and cross-link$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:22
16	2833	514/54	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
17	522	514/54 and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
18	192	(514/54 and cross-link$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
19	24	((514/54 and cross-link$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23

L Number	Hits	Search Text	DB	Time stamp
1	54180	polysaccharide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:45
2	8944	polysaccharide and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:46
3	1052	(polysaccharide and cross-link$) and polyamine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
4	328	((polysaccharide and cross-link$) and polyamine) and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
5	94	(((polysaccharide and cross-link$) and polyamine) and carboxy) and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
6	6568	polysaccharide and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
7	2134	(polysaccharide and carboxy) and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
8	476	((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
9	0	(((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and hyaluronicl4 and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
10	80	(((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
11	67	(((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and chitin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
12	535	536/21	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
13	94	536/21 and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
14	27	(536/21 and cross-link$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18

15	6	((536/21 and cross-link$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:22
16	2833	514/54	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
17	522	514/54 and cross-link$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
18	192	(514/54 and cross-link$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
19	24	((514/54 and cross-link$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:49
20	0	(((514/54 and cross-link$) and hyaluronic) and (diamine or polyamine)) and complex?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:49
21	130	((514/54 and cross-link$) and hyaluronic) and comple?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:50
22	57	(((514/54 and cross-link$) and hyaluronic) and comple?) and (copper or iron)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:52
23	76	((((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and hyaluronic) and (copper or iron or metal or ion)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:58
24	5	(((514/54 and cross-link$) and hyaluronic) and comple?) and salified	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:58
25	3	((((514/54 and cross-link$) and hyaluronic) and comple?) and salified) and (copper or iron or zinc)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:33
26	22	(((514/54 and cross-link$) and hyaluronic) and (diamine or polyamine)) and sulfat?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:00
27	0	((((514/54 and cross-link$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and trioxide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:00
28	30951	((((514/54 and cross-link$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and sulfur trioxide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:01

29	2	((((514/54 and cross-link$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:04
30	0	((((polysaccharide and carboxy) and cross-link$) and (diamine or triamine)) and hyaluronic) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:04
31	5	((536/21 and cross-link$) and hyaluronic) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:06
32	3	(((536/21 and cross-link$) and hyaluronic) and sulfation) and pyridine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:06
33	1	((514/54 and cross-link$) and hyaluronic) and complex?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:34
34	1	(((514/54 and cross-link$) and hyaluronic) and complex?) and (copper or zinc or iron)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:36
35	0	((((514/54 and cross-link$) and hyaluronic) and complex?) and (copper or zinc or iron)) and cross-link?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:36

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 26  Sep 16  CA Section Thesaurus available in CAPLUS and CA

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
```

FILE 'HOME' ENTERED AT 14:30:46 ON 23 SEP 2002

=> file polymers
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'BABS' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 14:31:14 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:31:14 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'DKILIT' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'IFIPAT' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'PASCAL' ENTERED AT 14:31:14 ON 23 SEP 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 14:31:14 ON 23 SEP 2002
Copyright (C) 2002 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TEXTILETECH' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 14:31:14 ON 23 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:31:14 ON 23 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 14:31:14 ON 23 SEP 2002

FILE 'WTEXTILES' ENTERED AT 14:31:14 ON 23 SEP 2002


```
=> s polysaccharide
L1      218150 POLYSACCHARIDE

=> s l1 and carboxy
L2        7277 L1 AND CARBOXY

=> s l2 and activat?
L3        3796 L2 AND ACTIVAT?

=> s l3 and cross-link
L4         317 L3 AND CROSS-LINK

=> s l4 and (diamine or polyamine)
L5          76 L4 AND (DIAMINE OR POLYAMINE)

=> s l5 and hyaluroni
L6           0 L5 AND HYALURONI

=> s l5 and hyaluronic
L7          24 L5 AND HYALURONIC

=> dis l7 1-24 bib abs

L7   ANSWER 1 OF 24  USPATFULL
AN     2002:235521  USPATFULL
TI     Process for ex vivo formation of mammalian bone and uses thereof
IN     Kale, Sujata, Boston, MA, UNITED STATES
       Long, Michael W., Northville, MI, UNITED STATES
PI     US 2002127711      A1   20020912
AI     US 2000-753043     A1   20001227 (9)
DT     Utility
FS     APPLICATION
LREP   Steven L. Highlander, Fulbright & Jaworski L.L.P.,, 600 Congress Avenue
       Suite 2400, Austin, TX, 78701
CLMN   Number of Claims: 38
ECL    Exemplary Claim: 1
DRWN   10 Drawing Page(s)
LN.CNT 3032
AB     The present invention concerns methods for the ex vivo formation of
       mammalian bone and subsequent uses of the bone. A critical and
       distinguishing feature of the present invention are defined tissue
       culture conditions and factors resulting in the formation of bone cell
       spheroids. The invention also provides for methods of implanting into
       subjects the ex vivo formed bone. Also described are methods for
       genetically altering the bone cell spheroids to affect bone formation,
       identification of candidate modulators of bone formation, and
       identification of genes involved in bone formation.


L7   ANSWER 2 OF 24  USPATFULL
AN     2002:224605  USPATFULL
TI     Lipid soluble steroid prodrugs
IN     Unger, Evan C., Tucson, AZ, United States
       Shen, DeKang, Tucson, AZ, United States
PA     Imarx Therapeutics, Inc., Tucson, AZ, United States (U.S. corporation)
PI     US 6444660         B1   20020903
AI     US 2000-496761          20000203 (9)
```

RLI Division of Ser. No. US 1997-851780, filed on 6 May 1997, now patented, Pat. No. US 6090800
DT Utility
FS GRANTED
EXNAM Primary Examiner: Badio, Barbara P.
LREP Woodcock Washburn LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6452
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel lipid soluble steroid prodrugs, compositions comprising steroid prodrugs, and uses of the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 24 USPATFULL
AN 2002:217089 USPATFULL
TI Methods of using polynucleotide compositions
IN Kabanov, Alexander V., Omaha, NE, United States
Alakov, Valery Y., Montreal, CANADA
Vinogradov, Serguie, Omaha, NE, United States
PA Supratek Pharma Inc., CANADA (non-U.S. corporation)
PI US 6440743 B1 20020827
AI US 1999-320640 19990526 (9)
RLI Division of Ser. No. US 1998-124943, filed on 30 Jul 1998, now patented, Pat. No. US 6221959 Continuation-in-part of Ser. No. US 1997-912968, filed on 1 Aug 1997, now patented, Pat. No. US 6353055 Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994, now patented, Pat. No. US 5656611
DT Utility
FS GRANTED
EXNAM Primary Examiner: McGarry, Sean; Assistant Examiner: Epps, Janet
LREP Mathews, Collins, Shepherd & McKay, P.A.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2206
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. The polynucleotide complex can further include a polycationic polymer, as well as suitable targeting molecules and surfactants. The invention also provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 24 USPATFULL
AN 2002:167866 USPATFULL
TI Acoustically active drug delivery systems
IN Unger, Evan C., Tucson, AZ, United States
PA Bristol-Myers Squibb Medical Imaging, Inc., Princeton, NJ, United States (U.S. corporation)
PI US 6416740 B1 20020709
AI US 1998-75343 19980511 (9)
PRAI US 1997-46379P 19970513 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dudash, Diana; Assistant Examiner: Sharareh, Shahnam
LREP Woodcock Washburn LLP

CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 5660
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic delivery systems are also embodied by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperature below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted therapeutic delivery system, wherein said processing is selected from the group consisting of controlled agitation, controlled drying, and a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 24 USPATFULL
AN 2002:72457 USPATFULL
TI SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME
IN UNGER, EVAN C., TUCSON, AZ, UNITED STATES
PI US 2002039594 A1 20020404
AI US 1998-75477 A1 19980511 (9)
PRAI US 1997-46379P 19970513 (60)
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN KURTZ, MACKIEWICZ AND NORRIS, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 106
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a solid porous matrix comprising a solvent and a surfactant in combination with a bioactive agent. The solvent and the surfactant may, if desired, form vesicles, an agglomeration of which comprises the matrix. The composition optionally comprises a gas or a gaseous precursor. The emulsion may be dried, and subsequently reconstituted in an aqueous or organic solution.

The present invention is also directed to a method of preparing a solid porous matrix comprising combining a solvent, a surfactant, and a therapeutic to form an emulsion; and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form a solid porous matrix. The resulting solid porous matrix may also comprise a gas or gaseous precursor and be added to a resuspending medium.

A method for the controlled delivery of a targeted therapeutic to a region of a patient is another embodiment of the present invention. The method comprises administering to the patient a composition having a solid porous matrix comprising a solvent, a surfactant, a therapeutic, and a gas or gaseous precursor, monitoring the composition using energy to determine the presence of the composition in the region; and releasing the therapeutic from the composition in the region using energy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 24 USPATFULL
AN 2002:57879 USPATFULL

TI Polynucleotide compositions for intramuscular administration
IN Lemieux, Pierre M., Ste.-Therese, CANADA
Kabanov, Alexander V., Omaha, NE, United States
Alakov, Valery Y., D'Urfe, CANADA
Vinogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma Inc., Doryal, United States (non-U.S. corporation)
PI US 6359054 B1 20020319
AI US 1999-227364 19990108 (9)
RLI Continuation-in-part of Ser. No. US 1998-124943, filed on 30 Jul 1998, now patented, Pat. No. US 6221959 Continuation-in-part of Ser. No. US 1997-912968, filed on 1 Aug 1997 Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994, now patented, Pat. No. US 5656611
DT Utility
FS GRANTED
EXNAM Primary Examiner: Szekely, Peter
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for intramuscular administration of polynucleotides, such as RNA, DNA, or derivatives thereof comprising polynucleotides and block copolymers of alkylethers. The invention also provides compositions and methods for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 24 USPATFULL
AN 2002:45673 USPATFULL
TI Polynucleotide compositions
IN Kabanov, Alexander Victorovich, Omaha, NE, United States
Alakov, Valery Yulievich, D'Urfe, CANADA
Vingogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma Inc., Quebec, CANADA (non-U.S. corporation)
PI US 6353055 B1 20020305
AI US 1997-912968 19970801 (8)
RLI Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994, now patented, Pat. No. US 5656611
DT Utility
FS GRANTED
EXNAM Primary Examiner: Szekely, Peter
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. Preferably, the polynucleotide complex will further include a polycationic polymer. The compositions can further include suitable targeting molecules and surfactants. In another aspect, the invention provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block. In yet another aspect, the invention provides polynucleotides 10 that have been covalently modified at their 5' or 3' end to attach a polyether polymer segment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 24 USPATFULL
AN 2002:37868 USPATFULL
TI Methods and compositions for sealing tissue leaks
IN Wilkie, James, Melrose, MA, UNITED STATES
Rolke, James, Fitzwilliam, NH, UNITED STATES
Burzio, Luis, Andover, MA, UNITED STATES
Tammishetti, Shekharam, Secunderabad, INDIA
Pendharkar, Sanyog Manohar, Oldbridge, NJ, UNITED STATES
PI US 2002022588 A1 20020221
AI US 2000-747293 A1 20001222 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US14232, filed on 23 Jun 1999, UNKNOWN
PRAI US 1998-90609P 19980623 (60)
US 2000-199469P 20000425 (60)
US 1999-171859P 19991222 (60)
DT Utility
FS APPLICATION
LREP TESTA, HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET, BOSTON, MA, 02110
CLMN Number of Claims: 167
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions that are useful for adhering biological and/or synthetic tissues, sealing fluid and/or gaseous leaks in biological and/or synthetic tissues, and preparing implants useful for delivery of a bioactive molecule such as a drug, for bulking applications, or for tissue prostheses. The present invention also relates to bio-erodable adhesive or occluding compositions and methods of using the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 24 USPATFULL
AN 2002:22133 USPATFULL
TI Novel drosophila tumor necrosis factor class molecule ("DmTNF") and variants thereof
IN Carroll, Pamela M., Princeton, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Xiao, Hong, Princeton Junction, NJ, UNITED STATES
Guan, Bo, Princeton, NJ, UNITED STATES
Bowen, Michael A., Lawrenceville, NJ, UNITED STATES
PI US 2002012968 A1 20020131
AI US 2001-813329 A1 20010320 (9)
PRAI US 2000-190816P 20000321 (60)
DT Utility
FS APPLICATION
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 9244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding Drosophila DmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and homologs thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, in addition to methods of genetically modifying

Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 24 USPATFULL
AN 2001:234992 USPATFULL
TI Nanogel networks and biological agent compositions thereof
IN Kabanov, Alexander V., Omaha, NE, United States
Vinogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma, Inc., Canada (non-U.S. corporation)
PI US 6333051 B1 20011225
AI US 1998-146651 19980903 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2246
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Copolymer networks having at least one cross-linked **polyamine** polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 24 USPATFULL
AN 2001:182086 USPATFULL
TI Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions
IN Unger, Evan C., Tucson, AZ, United States
PA ImaRx Pharmaceutical Corp. (U.S. corporation)
PI US 2001031243 A1 20011018
AI US 2001-813484 A1 20010321 (9)
RLI Division of Ser. No. US 1997-929847, filed on 15 Sep 1997, PENDING
DT Utility
FS APPLICATION
LREP Woodcock Washburn Kurtz, Mackiewicz & Norris LLP, 46th Floor, One Liberty Place, Philadelphia, PA, 19103
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled compositions to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 24 USPATFULL
AN 2001:167740 USPATFULL
TI Composition for treating benign prostatic hypertrophy

IN Gokcen, Muharrem, Minneapolis, MN, United States
Guy, Terry J., Chaska, MN, United States
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)
PI US 6296847 B1 20011002
AI US 1993-154158 19931117 (8)
RLI Continuation of Ser. No. US 1991-707662, filed on 30 May 1991, now abandoned Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned Continuation-in-part of Ser. No. US 1989-303809, filed on 27 Jan 1989, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Witz, Jean C.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a composition and method for treating benign prostatic hypertrophy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 24 USPATFULL
AN 2001:144937 USPATFULL
TI Solid matrix therapeutic compositions
IN Unger, Evan C., Tucson, AZ, United States
PA ImaRx Therapeutics, Inc. (U.S. corporation)
PI US 2001018072 A1 20010830
AI US 2001-828762 A1 20010409 (9)
RLI Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING
PRAI US 1997-46379P 19970513 (60)
DT Utility
FS APPLICATION
LREP Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a solid porous matrix comprising a surfactant in combination with a bioactive agent. The solid porous matrix may be prepared by combining a surfactant and a therapeutic, together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form the solid porous matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 24 USPATFULL
AN 2001:130897 USPATFULL
TI Prolonged release of GM-CSF
IN Gombotz, Wayne R., Kirkland, WA, United States
Pettit, Dean K., Seattle, WA, United States

Pankey, Susan C., Yardley, PA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6274175 B1 20010814
AI US 1999-442370 19991117 (9)
RLI Continuation of Ser. No. US 1998-185213, filed on 3 Nov 1998, now patented, Pat. No. US 6120807 Division of Ser. No. US 1995-542445, filed on 12 Oct 1995, now patented, Pat. No. US 5942253
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A
LREP Sheiness, Diana K.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 24 USPATFULL
AN 2001:97899 USPATFULL
TI Autocross-linked **hyaluronic** acid and related pharmaceutical compositions for the treatment of arthropathies
IN Bellini, Davide, Padua, Italy
Paparella, Annamaria, Bari, Italy
O'Regan, Michael, Padua, Italy
Callegaro, Lanfranco, Vicenza, Italy
PA Fidia, S.p.A., Abano Terme, Italy (non-U.S. corporation)
PI US 6251876 B1 20010626
WO 9749412 19971231
AI US 1999-202817 19990625 (9)
WO 1997-EP3238 19970620
19990625 PCT 371 date
19990625 PCT 102(e) date
PRAI IT 1996-PD163 19960621
DT Utility
FS GRANTED
EXNAM Primary Examiner: Peselev, Elli
LREP Birch, Stewart, Kolasch & Birch LLP, Svensson, Leonard R.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,2,8
DRWN 19 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions containing an autocross-linked form of **hyaluronic** acid as a first component in a mixture with a second component noncross-linked **hyaluronic** acid, and possibly also in combination with another pharmacologically active substance. These compositions can be used in the treatment of arthropathies due to their unique viscoelastic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 24 USPATFULL
AN 2001:59978 USPATFULL
TI Polynucleotide compositions
IN Kabanov, Alexander V., Omaha, NE, United States
Alakov, Valery Y., D'Urfe, Canada
Vinogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma, Inc., Montreal, Canada (non-U.S. corporation)
PI US 6221959 B1 20010424
AI US 1998-124943 19980730 (9)
RLI Continuation-in-part of Ser. No. US 1998-912968, filed on 1 Aug 1998
Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994, now patented, Pat. No. US 5656611
DT Utility
FS Granted
EXNAM Primary Examiner: Michl, Paul R.
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. The polynucleotide complex can further include a polycationic polymer, as well as suitable targeting molecules and surfactants. The invention also provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 24 USPATFULL
AN 2000:124586 USPATFULL
TI Prolonged release of GM-CSF
IN Gombotz, Wayne, Kirkland, WA, United States
Pettit, Dean, Seattle, WA, United States
Pankey, Susan, Seattle, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6120807 20000919
AI US 1998-185213 19981103 (9)
RLI Division of Ser. No. US 1995-542445, filed on 12 Oct 1995, now patented, Pat. No. US 5942253
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1382
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic

acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments hare been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 24 USPATFULL
AN 2000:91955 USPATFULL
TI Lipid soluble steroid prodrugs
IN Unger, Evan C., Tucson, AZ, United States
Shen, DeKang, Tucson, AZ, United States
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6090800 20000718
AI US 1997-851780 19970506 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel lipid soluble steroid prodrugs compositions comprising steroid prodrugs, and uses of the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 24 USPATFULL
AN 2000:87694 USPATFULL
TI Compositions of microspheres for wound healing
IN Ritter, Vladimir, Kiriat-Yam, Israel
Ritter, Marina, Kiriat-Yam, Israel
PA Polyheal Ltd., Haifa, Israel (non-U.S. corporation)
PI US 6086863 20000711
AI US 1998-177954 19981023 (9)
RLI Continuation-in-part of Ser. No. US 1997-868950, filed on 4 Jun 1997, now patented, Pat. No. US 5861149
DT Utility
FS Granted
EXNAM Primary Examiner: Cintins, Marianne M.; Assistant Examiner: Kim, Vickie
LREP Graham & James LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 1659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Therapeutic compositions of microspheres for application to wounds and/or lesions for accelerating wound healing and muscle regeneration. The microspheres are made up of non-biodegradable material having a

substantial surface charge. The therapeutic composition further includes a pharmaceutically acceptable carrier in which the microspheres are insoluble and a container for holding the composition. The therapeutic composition further contains pharmacologic agents or biologics that accelerate the wound healing process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 24 USPATFULL
AN 2000:21560 USPATFULL
TI Prodrugs comprising fluorinated amphiphiles
IN Unger, Evan C., Tucson, AZ, United States
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6028066 20000222
AI US 1997-887215 19970702 (8)
RLI Continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes, inter alia, novel prodrugs comprising fluorinated amphiphiles, compositions comprising the novel prodrugs, and methods of use of the prodrugs and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 24 USPATFULL
AN 1999:99401 USPATFULL
TI Prolonged release of GM-CSF
IN Gombotz, Wayne, Kirkland, WA, United States
Pettit, Dean, Seattle, WA, United States
Pankey, Susan, Seattle, WA, United States
Lawter, James Ronald, Goshen, NY, United States
Huang, W. James, Sommerville, NJ, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
American Cyanamid Company, Pearl River, NY, United States (U.S. corporation)
PI US 5942253 19990824
AI US 1995-542445 19951012 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For

example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 24 USPATFULL
AN 1998:75722 USPATFULL
TI Products comprising substrates capable of enzymatic cross-linking
IN Cappello, Joseph, San Diego, CA, United States
PA Protein Polymer Technologies, San Diego, CA, United States (U.S. corporation)
PI US 5773577 19980630
AI US 1995-397633 19950302 (8)
RLI Continuation-in-part of Ser. No. US 1994-205518, filed on 3 Mar 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner: Stole, Einar
LREP Trecartin, Richard F.Flehr Hohbach Test Albritton & Herbert LLP
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3006
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polymers are provided comprising protein polymers comprising blocks of repeating units and sequences comprising amino acids, individually or in defined sequences, capable of enzyme catalyzed covalent bond formation for cross-linking, as exemplified by glutamine and/or lysine reactive for FXIII catalyzed isopeptide formation or non-amino acid polymers having side chains comprising such amino acids or sequences, which may be used for preparation of articles of manufacture, particularly cross-linkable compositions. By appropriate choice of the polymer, resorbable implantable polymers may be used in internal applications for mammals as formed objects or depots.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 24 USPATFULL
AN 97:93905 USPATFULL
TI Crosslinked **carboxy polysaccharides**
IN Della Valle, Francesco, Padua, Italy
Romeo, Aurelio, Rome, Italy
PA Fidia, S.p.A., Abano Terme, Italy (non-U.S. corporation)
PI US 5676964 19971014
AI US 1995-465055 19950605 (8)
RLI Continuation of Ser. No. US 1993-70505, filed on 1 Jun 1993 which is a continuation of Ser. No. US 1989-350919, filed on 12 May 1989, now abandoned
PRAI IT 1988-47964 19880513
DT Utility
FS Granted
EXNAM Primary Examiner: Peselev, Elli
LREP Birch, Stewart, Kolasch & Birch, LLP
CLMN Number of Claims: 65
ECL Exemplary Claim: 1,36
DRWN No Drawings
LN.CNT 2523

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Inter and/or intramolecular cross-linked esters of acid **polysaccharides** are disclosed in which a part or all of the **carboxy** groups are esterified with hydroxyl groups of the same molecule and/or of different molecules of the acid **polysaccharide**. These inner cross-linked esters of **polysaccharide** acids are useful in the field of biodegradable plastic materials, to manufacture sanitary and surgical articles, in the cosmetic and pharmaceutical fields, in the food industry and in many other industrial fields.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 24 USPATFULL
AN 92:42541 USPATFULL
TI Method for treating benign prostatic hypertrophy
IN Gokcen, Muharrem, Minneapolis, MN, United States
Guy, Terry J., Chaska, MN, United States
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)
PI US 5116615 19920526
AI US 1991-707628 19910530 (7)
RLI Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-303809, filed on 27 Jan 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Stone, Jacqueline
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a composition and method for treating benign prostatic hypertropy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 14:30:46 ON 23 SEP 2002)

FILE 'BABS, CAPLUS, CBNB, CEN, CIN, DKILIT, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPINDEX, WTEXTILES' ENTERED AT 14:31:14 ON 23 SEP 2002
L1 218150 S POLYSACCHARIDE
L2 7277 S L1 AND CARBOXY
L3 3796 S L2 AND ACTIVAT?
L4 317 S L3 AND CROSS-LINK
L5 76 S L4 AND (DIAMINE OR POLYAMINE)
L6 0 S L5 AND HYALURONI
L7 24 S L5 AND HYALURONIC

=> s l7 and sulfation
L8 1 L7 AND SULFATION

=> dis 18 bib abs

L8 ANSWER 1 OF 1 USPATFULL
AN 2002:22133 USPATFULL
TI Novel drosophila tumor necrosis factor class molecule ("DmTNF") and variants thereof
IN Carroll, Pamela M., Princeton, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Xiao, Hong, Princeton Junction, NJ, UNITED STATES
Guan, Bo, Princeton, NJ, UNITED STATES
Bowen, Michael A., Lawrenceville, NJ, UNITED STATES
PI US 2002012968 A1 20020131
AI US 2001-813329 A1 20010320 (9)
PRAI US 2000-190816P 20000321 (60)
DT Utility
FS APPLICATION
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 9244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding Drosophila DmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and homologs thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, in addition to methods of genetically modifying Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file chemistry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	93.06	93.27

FILE 'AGRICOLA' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'ALUMINIUM' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUIRE' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 US Environmental Protection Agency (EPA)

FILE 'BABS' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'BIOCOMMERCE' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOTECHNO' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CABA' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CAOLD' ENTERED AT 14:36:29 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'CAPLUS' ENTERED AT 14:36:29 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'CBNB' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CEABA-VTB' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CEN' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CERAB' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CIN' ENTERED AT 14:36:29 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'COMPENDEX' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CONFSCI' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'COPPERLIT' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'CORROSION' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'DKILIT' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'ENCOMPLIT' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'ENCOMPLIT2' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'FEDRIP' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'GENBANK' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'INSPEC' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INSPHYS' ENTERED AT 14:36:29 ON 23 SEP 2002
Compiled and produced by the IEE in association with FIZ KARLSRUHE
COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INVESTEXT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'IPA' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'METADEX' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'NAPRALERT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NIOSHTIC' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:36:29 ON 23 SEP 2002
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2002)

FILE 'PAPERCHEM2' ENTERED AT 14:36:29 ON 23 SEP 2002
Paperchem2 compilation and indexing (C) 2002
Elsevier Engineering Information Inc. All rights reserved.

FILE 'PASCAL' ENTERED AT 14:36:29 ON 23 SEP 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'RUSSCI' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Andrigal Ltd.

FILE 'SCISEARCH' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TULSA' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'USAN' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'WELDASEARCH' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'WSCA' ENTERED AT 14:36:29 ON 23 SEP 2002


```
=> s polysaccharide
L9      239171 POLYSACCHARIDE

=> s l9 and carboxy
L10        628 L9 AND CARBOXY

=> s l10 and activat?
  26 FILES SEARCHED...
L11         40 L10 AND ACTIVAT?

=> s l11 and cross-link?
  25 FILES SEARCHED...
L12          1 L11 AND CROSS-LINK?

=> dis l12 bib abs

L12  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
AN   1990:406740  CAPLUS
DN   113:6740
TI   Preparation of crosslinked carboxy polysaccharides as
     biodegradable plastic materials for cosmetics and pharmaceuticals
IN   Della Valle, Francesco; Romeo, Aurelio
PA   Fidia S.p.A., Italy
SO   Eur. Pat. Appl., 37 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
PI   EP 341745          A1   19891115       EP 1989-108630    19890512
     EP 341745          B1   19941214
         R:  AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
     WO 8910941         A1   19891116       WO 1989-EP519     19890512
         W:  AU, DK, FI, HU, JP, KR
     AU 8935747         A1   19891129       AU 1989-35747     19890512
     AU 631125          B2   19921119
     HU 53666           A2   19901128       HU 1989-3636      19890512
     HU 210926          B    19950928
     JP 02504163        T2   19901129       JP 1989-505458    19890512
     JP 2941324         B2   19990825
     EP 614914          A2   19940914       EP 1994-108633    19890512
     EP 614914          A3   19941228
     EP 614914          B1   20000816
         R:  AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
     ES 2064378         T3   19950201       ES 1989-108630    19890512
     IL 90274           A1   19960912       IL 1989-90274     19890512
     CA 1339122         A1   19970729       CA 1989-599557    19890512
     JP 10324701        A2   19981208       JP 1998-152832    19890512
     AT 195534          E    20000915       AT 1994-108633    19890512
     ES 2151910         T3   20010116       ES 1994-108633    19890512
     DK 9000109         A    19900312       DK 1990-109       19900112
     US 5676964         A    19971014       US 1995-465055    19950605
PRAI IT 1988-47964      A    19880513
     EP 1989-108630     A3   19890512
     JP 1989-505458     A3   19890512
     US 1989-350919     B1   19890512
     WO 1989-EP519      A    19890512
     US 1993-70505      A1   19930601
AB   Inter- and/or intramol. esters of acid polysaccharides contg.
```

carboxy functions (e.g. auto-crosslinked **polysaccharides**), wherein (1) a first portion or all of the **carboxy** groups are esterified with hydroxy groups of the same mol. and/or of different mols. of the acid **polysaccharide** and/or (2) a second portion of the **carboxy** groups are esterified with a mono- or polyvalent alcs. including various drugs (e.g. alkaloids, anesthetic, analgesic, antiinflammatory, antiviral, antibacterial, etc.) and optionally salified with an alkali or alk. earth metal, Mg, Al, or an amine including various drugs (e.g. alkaloids, peptides, antipsychotics, phenothiazine, vasoconstrictors, etc.), are prepd. by treating an acidic **polysaccharide** (e.g., hyaluronic acid, alginic acid, CM-cellulose, carboxymethylchitin) with an **activating** agent (e.g. 2-chloro-1-methylpyridinium iodide) and subjecting the resulting intermediate **activated polysaccharide** derivs. to heat or irradn. These auto-crosslinked **polysaccharide** acids are useful in the field of biodegradable plastic materials to manuf. sanitary and surgical articles (e.g. surgical suture thread, film for artificial skin, and sponges for the medication of wounds and lesions), for pharmaceutical vehicles for controlled-release of drugs (capsules for the s.c. implantation of medicaments or microcapsules for s.c., i.m., or i.v. injection), etc.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	70.18	163.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 14:39:42 ON 23 SEP 2002